US Pat. No. 9,314,014

COMPOSITIONS AND METHODS FOR THE STORAGE OF RED BLOOD CELLS

University of Maryland, B...

1. An aqueous composition, in a volume ratio of 1:4.5 of solution to whole blood collected, for storage of red blood cells
at about 1 to about 6° C., the composition free of exogenously derived chloride ions and consisting of:
adenine;
dextrose in an amount of from about 60 to about 100 mM;
at least one non-metabolizable membrane-protectant sugar; and
a pH buffering system,wherein the pH buffering system consists of sodium bicarbonate in an amount of about 26 mM, and disodium phosphate, wherein
the pH buffering system is present in an amount sufficient for the composition to be operable to maintain a pH of a red blood
cell suspension to which the composition is added at a value sufficient to establish and maintain during a storage period
a reaction equilibrium in the red blood cells that favors glycolysis over synthesis of 2,3-diphosphoglycerate (DPG) from 1,3-DPG,
thereby generating a net gain in adenosine tri phosphate (ATP) synthesis with respect to the reaction equilibrium during the
storage period.
US Pat. No. 9,757,432

MATERIALS AND METHODS USEFUL FOR TREATING GLIOBLASTORNA

Ohio State Innovation Fou...

1. A method to induce cell death in at least one glioblastoma cancer cell, comprising:
a) administering from about 0.55 ?M to about 17.5 ?M of a SapC-DOPS composition to at least one glioblastoma cancer cell;
and,

b) administering from about 1 nM to about 50 nM of a rapamycin compound to the at least one glioblastoma cancer cell;
the SapC-DOPS composition and rapamycin compound being present in amounts sufficient for inducing cell death in the at least
one glioblastoma cancer cell;

wherein the SapC-DOPS composition comprises:
a phospholipid comprising dioleoylphosphatidylserine (DOPS);
an isolated saposin C-related polypeptide consisting of SEQ ID NO:2;
and a pharmaceutically acceptable carrier;
wherein the rapamycin compound comprises sirolimus; and,
wherein the DOPS phospholipid forms a nanovesicle incorporating the saposin C-related polypeptide.
US Pat. No. 9,409,975

ANTIBODY BINDING MICROBIAL HEPARIN BINDING MOTIF TO RETARD OR PREVENT MICROBIAL BIOFILM FORMATION ON IMPLANTED MEDICAL DEVICES

University of Cincinnati,...

1. A composition comprising at least one biocompatible excipient and an antibody capable of binding to peptide HKQEKQKKHQIHKV
(SEQ ID NO: 4) wherein the excipient comprises a Tris buffer and wherein the antibody is a non-human humanized antibody.
US Pat. No. 9,114,148

MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS

University of Cincinnati,...

1. A method of increasing cardiac contractility and reducing morphological deterioration associated with cardiac remodeling
in a subject with existing heart failure, said method comprising:
directly introducing in vivo an effective amount of a viral vector into the lumen of a coronary artery of the heart of the
subject by percutaneous intracoronary gene transfer, wherein said viral vector is an adeno-associated viral vector (AAV) comprising
a nucleic acid sequence encoding a polypeptide consisting of amino acids 1-65 of SEQ ID NO: 2, wherein threonine at position
35 of SEQ ID NO: 2 is replaced with an aspartic acid; and wherein said nucleic acid sequence is operably linked to a promoter
capable of directing expression in the heart;

thereby expressing the fragment in the heart of the subject in an amount effective to increase cardiac contractility and reduce
morphological deterioration associated with cardiac remodeling in the subject with existing heart failure.

US Pat. No. 10,096,154

LOCALIZED CONTOUR TREE METHOD FOR DERIVING GEOMETRIC AND TOPOLOGICAL PROPERTIES OF COMPLEX SURFACE DEPRESSIONS BASED ON HIGH RESOLUTION TOPOGRAPHICAL DATA

University of Cincinnati,...

1. A computer-implemented method for detecting and characterizing surface depressions in a topographical area, the method comprising:a) providing a digital elevation model (DEM) of the topographical area, wherein the DEM is derived from high resolution digital elevation data collected by Light Detecting and Ranging (LiDAR) or Interferometric Synthetic Aperture Radar (InSAR) technology;
b) designating a base elevation contour and a contour interval for the DEM;
c) using the base elevation contour and interval from b), generating an elevation contour representation of the topographical area, wherein the contour representation comprises closed contour lines and excludes open contour lines;
d) identifying one or more seed contours, defined as a lowest elevation interior contour in a set of concentric closed contours, and, beginning with the lowest elevation seed contour and hierarchically expanding to higher elevation contours until a highest elevation contour is reached, constructing a local contour tree, wherein each contour line is represented as a node in the local contour tree;
e) repeating step (d) iteratively until all highest elevation contours are incorporated in a local contour tree;
wherein the number of surface depressions corresponds to the number of local contour trees, a simple depression comprises a local contour tree with one seed node, and a complex depression comprises a local contour tree with more than one seed node;
f) identifying a quasi-pour contour node for each local contour tree; and
g) determining a true-pour contour node for each local contour tree, wherein an elevation of a true pour contour node is a spill elevation and an elevation of a quasi-pour contour node is less than or equal to the elevation of the true pour contour node.
US Pat. No. 9,920,113

ANTIBODY BINDING MICROBIAL HEPARIN BINDING MOTIF TO RETARD OR PREVENT MICROBIAL BIOFILM FORMATION ON IMPLANTED MEDICAL DEVICES

UNIVERSITY OF CINCINNATI,...

1. A method to reduce or inhibit biofilm formation on a surface of an indwelling or implanted medical device in a patient,
the method comprising administering before, during, and/or after installation or implantation of the medical device in the
patient an effective amount of a composition, the composition comprising
at least one biocompatible excipient and an antibody that binds isolated peptide HKQEKQKKHQIHKV (SEQ ID NO: 4) or that binds
a fragment of at least seven contiguous amino acids of SEQ ID NO: 4; or the composition comprising

at least one biocompatible excipient and isolated peptide HKQEKQKKHQIHKV (SEQ ID NO: 4) or a fragment of at least seven contiguous
amino acids of SEQ ID NO: 4,
the administering occurring under conditions to result in reduced heparin-binding to a surface of the implanted medical device,
resulting in reduced or inhibited biofilm formation on the medical device.

US Pat. No. 9,921,167

OPTICAL SENSOR BASED ON PFSI MEMBRANE COMPRISING ASSOCIATED BENZENE-1,3-DIOL FOR DETECTING TARGET COMPOUNDS, AND METHOD THEREOF

University of Cincinnati,...

1. A method of monitoring for presence of a target compound in an environment in gas phase via an optical sensor comprising
a solid state perfluorosulfonate ionomer (PFSI) membrane comprising perfluorosulfonic acid functional groups and benzene-1,3-diol
immobilized in the membrane within a proximity to the perfluorosulfonic acid functional groups necessary to effectuate acid
catalysis of a reaction between the benzene-1,3-diol and the target compound sufficient to produce a detectable color shift
on the PFSI membrane when the membrane is exposed to the target compound in gas phase, the method comprising:
exposing the optical sensor to an environment; and
examining the optical sensor for a detectable color shift indicating presence of the target compound.
US Pat. No. 9,868,786

METHODS FOR SUPPRESSING ALLERGIC REACTIONS

University of Cincinnati,...

1. A method of treating a subject suffering from an allergic disorder, the method comprising inducing rapid desensitization
to an allergen, said rapid desensitization effectuated by:
a. providing a monoclonal antibody selected from the group consisting of anti-Fc?RIa and an antibody that specifically binds
Fc?RIIb and Fc?RIII;

b. administering the monoclonal antibody to the subject at a dose that is lower than a level required to induce shock; and
c. administering sequentially escalating doses of the monoclonal antibody, wherein 8 to 10 total doses are administered in
a single 24 hour period, thereby inducing rapid desensitization to the allergen.

US Pat. No. 9,434,764

SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR

University of Cincinnati,...

1. A peptide agonist of melanocortin 1 receptor (MC1R) selective for MC1R versus melanocortin 3 receptor (MC3R), melanocortin
4 receptor (MC4R), and melanocortin 5 receptor (MC5R) according to the following formula:
Ar(CH2)mX1—X2—CO—X3—X4—X5-(Trp)n-NX6R  Formula I

or a dermatologically-acceptable salt, solvate, or enantiomer thereof, wherein:
Ar is selected from the group consisting of unsubstituted or substituted phenyl and 5- or 6-membered heteroaryl;
m is 0, 1, 2, or 3;
X1 is absent or X1 is selected from the group consisting of O, NR?, S, Se, and CR?R? wherein R? is selected from the group consisting of H, linear
or branched C1-C4 alkyl, OH, and linear or branched C1-C4 O-alkyl and R? is selected from the group consisting of H and linear
or branched C1-C4 alkyl; or wherein CR?R? is a C3-C6 cycloalkyl;

X2 is absent or X2 is selected from the group consisting of 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, and CQ?Q? wherein Q? and Q? are each
independently selected from the group consisting of H and linear or branched C1-C4 alkyl;

X3 is selected from the group consisting of unsubstituted or substituted L-histidine (His), 3-(2-pyridyl)-L-alanine (2-PAL),
3-(3-pyridyl)-L-alanine (3-PAL), 3-(4-pyridyl)-L-alanine (4-PAL), 3-(2-thienyl)-L-alanine (2-Thi), 3-(3-thienyl)-L-alanine
(3-Thi), 3-(2-furyl)-L-alanine (2-FurAla), 3-(3-furyl)-L-alanine (3 FurAla), L-homoserine (HoSer), O-methyl-L-homoserine (HoSer(Me)),
and L-allylglycine;

X4 is selected from the group consisting of unsubstituted or substituted L-alpha-MePhe, 3-(2-thienyl)-D-alanine (D-2-Thi), 3-(3-thienyl)-D-alanine
(D-3-Thi), 3-(2-furyl)-D-alanine (D-2-FurAla), 3-(3-furyl)-D-alanine (D-3-FurAla), and substituted D-phenylalanine (D-Phe);

X5 is selected from the group consisting of unsubstituted or substituted L-arginine (Arg) and L-citrulline;

n is 0 or 1;
X6 is selected from the group consisting of H, linear or branched C1-C4 alkyl, and C3-C4 cycloalkyl; and

R is selected from the group consisting of H, linear or branched C1-C12 alkyl, linear or branched C1-C12 arylalkyl, and C3-C5
cycloalkyl;

or wherein X6 and R together form a C3-C5 heterocycloalkyl.

US Pat. No. 9,233,099

METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM

University of Cincinnati,...

1. A method for treating cognitive dysfunction in a subject having a creatine deficiency in the brain due to creatine transporter
dysfunction, the method comprising administering to said subject an effective amount of cyclocreatine or a pharmaceutically
acceptable salt thereof.

US Pat. No. 9,394,233

ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS

University of Cincinnati,...

1. A compound according to Formula I:
wherein:
R1 and R2 are each independently selected from the group consisting of substituted or unsubstituted or branched alkyl and unsubstituted
aryl wherein said alkyl and aryl optionally comprise one or more heteroatoms;

R3 is selected from the group consisting of OH, NHC(O)CH3, piperidine and OC(O)CH3; and n is 1-5,

wherein at least one of R1 and R2 is aryl.

US Pat. No. 9,387,066

ELEMENTS FOR VERSATILITY OF A PROSTHETIC ANCHOR

University of Cincinnati,...

1. A prosthetic anchor for attaching to and extending between a first natural tissue and a second natural tissue or prosthetic
structure in a subject, comprising;
a plurality of fiber bundles, each fiber bundle of the plurality of fiber bundles having a medial portion that substantially
defines a generally horseshoe-shaped pattern having first and second branches extending from the medial portion, the medial
portion being contained within a central layer;

a first plurality of tension elements extending from the first branch and a second plurality of tension elements extending
from the second branch, the first and second plurality of tension elements extending to and operatively connected to a tissue
engaging portion, the tissue engaging portion configured to extend through the first natural tissue and to disperse therein
with a proliferation of cells;

a first partial envelope and a second partial envelope positioned adjacent to and spaced away from one another and defining
a space therebetween, each of the first and second partial envelopes enclosing at least a portion of the central layer and
configured to interface with the second natural tissue or prosthetic structure;

the first partial envelope surrounding at least a portion of the first branch of the plurality of fiber bundles; and
the second partial envelope surrounding at least a portion of the second branch of the plurality of fiber bundles,
wherein at least a portion of the medial portion of the plurality of fiber bundles is positioned within the space between
the first and second partial envelopes; and further,

wherein the central layer is a wafer-like structure, the wafer-like structure defines a plurality of pathways, and the plurality
of fiber bundles are embedded respectively within the plurality of pathways.

US Pat. No. 9,180,454

ELECTROWETTING AND ELECTROFLUIDIC DEVICES WITH LAPLACE BARRIERS AND RELATED METHODS

University Of Cincinnati,...

1. A device comprising:
a first polar fluid;
a non-polar fluid;
a first substrate;
a second substrate arranged relative to the first substrate to define a hydrophobic channel containing the first polar fluid
and the non-polar fluid;

a first electrode on the first substrate;
a dielectric layer between the first electrode and the first polar fluid;
a first Laplace barrier within the hydrophobic channel, the first Laplace barrier defining a fluid pathway open to movement
of the first polar fluid within the hydrophobic channel; and

a first voltage source electrically connected with the first electrode, the first voltage source configured to electrically
bias the first electrode to cause the first polar fluid to move within the hydrophobic channel relative to the first Laplace
barrier,

wherein the first polar fluid is moved to a first position within the hydrophobic channel when the first electrode is biased
by the first voltage source with a first voltage that is less than or equal to a threshold voltage, and the first polar fluid
moves from the first position to a second position within the hydrophobic channel when the first electrode is biased by the
first voltage source with a second voltage that is greater than the threshold voltage, and

wherein the first Laplace barrier includes one or more hydrophobic spacers dividing the fluid pathway into a plurality of
openings each at least partially occupied by the first polar fluid at the second position.

US Pat. No. 9,051,394

APOLIPOPROTEIN AIV AS AN ANTIDIABETIC PEPTIDE

University of Cincinnati,...


US Pat. No. 9,297,013

PRNA MULTIVALENT JUNCTION DOMAIN FOR USE IN STABLE MULTIVALENT RNA NANOPARTICLES

University of Cincinnati,...

1. A multivalent RNA junction scaffold, comprising: a multiple RNA oligomer-formed polymer complex, wherein said polymer complex
is configured to promote an array of thermodynamically and stoichiometrically stable RNA nanoparticles, wherein said multivalent
RNA junction scaffold comprises a branched junction domain, said branched junction domain comprises groups of RNA polynucleotide
helical regions, each said helical region has defined number of RNA nucleotide base pairs that form Watson-Crick bonds, wherein
said groups of RNA polynucleotide helical regions comprise at least one unpaired RNA nucleotide base that is situated between
at least two helical regions, and 3 unpaired RNA nucleotides situated at a 3? end of at least one helical region.

US Pat. No. 9,200,037

COMPOUNDS FOR CONTROL OF APPETITE

University of Cincinnati,...

1. A compound of the formula:

wherein:
each X, independently, is an aromatic amino acid;
each Y, independently, is an amino acid having a guanidino group;
each Z, independently, is an aliphatic amino acid;
n=1, 2, 3 or 4; and
wherein the compound optionally includes one or two pseudopeptide bonds where each pseudopeptide bond is independently selected
from —CH2—NH—, —CH2—S—, —CH2—CH2—, —CH2—O— and CH2—CO—.

US Pat. No. 10,131,954

METHODS FOR DETECTION AND QUANTIFICATION OF EGFRVIII IN THE PERIPHERAL BLOOD OF GBM PATIENTS

University of Cincinnati,...

1. A method for monitoring the therapy of a patient suffering from glioblastoma multiforme (GBM), comprising:(a) subjecting a tumor sample from the patient comprising genomic DNA to long range polymerase chain reaction amplification of epithelial growth factor receptor vIII (EGFRvIII) gene, wherein the long range polymerase chain reaction amplification utilizes a plurality of primers, the primers comprising:
a plurality of forward primers corresponding to a DNA sequence in intron 1 of an epithelial growth factor receptor (EGFR) gene and comprising a combination of primers of Set A and Set B in Table 1, a forward primer that corresponds to a DNA sequence in exon 1 of an EGFR gene and comprises the nucleotide sequence (5?-GTCGGGCTCTCGAGGAAAAGAAAG-3?) (SEQ ID NO: 1), and a reverse primer that corresponds to a DNA sequence in exon 8 of an EGFR gene and comprises nucleotide sequence (5?-CTTCCTCCATCTCATAGCTGTCGG-3?) (SEQ ID NO: 2), such that if the sample comprises genomic DNA comprising EGFRvIII, a PCR product is formed, and if the sample does not comprise genomic DNA comprising EGFRvIII, a PCR product is not formed, wherein the plurality of forward primers corresponding to a DNA sequence in intron 1 of an epithelial growth factor receptor (EGFR) gene are comprised within the base pairs defining intron 1 of the EGFR, each primer being separated by at least 5 kb from each other, and wherein the presence of PCR product is indicative of a presence of EGFRvIII in the sample, and the absence of PCR product is indicative of an absence of EGFRvIII in the sample;
(b) identifying deletion breakpoints in the PCR product and designing amplification primers that hybridize to priming sites that flank the breakpoints, wherein the amplification primers are designed to yield a PCR fragment of about 300 base pairs;
(c) amplifying DNA from body fluid samples of said patient using the designed amplification primers from step (b) to form an amplified DNA fragment of EGFRvIII; and
(d) determining the amount or proportion of the amplified DNA fragment of EGFRvIII from step (c) in the body fluid samples of said patient.
US Pat. No. 9,951,120

METHOD OF TREATING DIABETES USING NON-GLYCOSYLATED APOLIPOPROTEIN A-IV

University of Cincinnati,...


US Pat. No. 9,873,915

GRADING, STAGING AND PROGNOSING CANCER USING OSTEOPONTIN-C

Ventana Medical Systems, ...

1. A method of treating a patient having a triple negative breast cancer tumor, the method comprising:
(I) grading the triple negative breast cancer tumor in the patient by:
(1) obtaining a sample of the triple negative breast cancer tumor from the patient;
(2) contacting the sample of the triple negative breast cancer tumor with an antibody that specifically binds to the splice
junction of the OPN-c protein under conditions suitable to form a complex of the OPN-c protein and the antibody, wherein the
antibody is anti-human OPN-c IgY;

(3) detecting the expression intensity level of the OPN-c protein in the sample contacted with the antibody in (I)(2) via
immunohistochemical staining; and

(4) quantifying the expression intensity level of the OPN-c protein detected in the sample in (I)(3); and
(5) grading the tumor on the basis of OPN-c expression intensity level; and
(II) treating the patient with:
(1) an aggressive therapeutic protocol when the triple negative breast cancer tumor has a grade of 2 or 3 on the basis of
OPN-C protein expression level, wherein the aggressive therapeutic protocol comprises mastectomy or lumpectomy combined with
radiotherapy and/or chemotherapy; and

(2) a less aggressive therapeutic protocol when the triple negative breast cancer tumor has a grade of 1 on the basis of OPN-C
protein expression level, wherein the less aggressive therapeutic protocol consists of lumpectomy.

US Pat. No. 9,487,816

METHODS OF DETECTING INFLUENZA VIRUS

University of Cincinnati,...

1. A method of treating a human patient by distinguishing presence of influenza virus in a sample from presence of one or
more other pathogens in the sample, the method comprising measuring enzymatic activity of neuraminidase (NA) in the sample
under one or more differentiating conditions selected from the group consisting of NA enzymatic activity determination at
a plurality of pH values, binding to anti-NanA antibody, size exclusion, hemagglutinin (HA) binding, chemical inhibition,
and combinations thereof, wherein the one or more differentiating conditions is NA enzymatic activity determination at a plurality
of pH values and the method comprises:
(a) providing a biological sample obtained from the patient, wherein the sample is suspected of comprising influenza virus;
(b) contacting the sample with a substrate for indicating NA enzymatic activity at a plurality of pH values ranging from about
pH 4 to about pH 10, wherein NA acts on the substrate to elicit a measurable response;

(c) measuring the response of step (b) at the plurality of pH values;
(d) correlating the response at the plurality of pH values to determine relative NA enzymatic activity at the plurality of
pH values, wherein

(i) maximal NA enzymatic activity at about pH 4 to about pH 5, compared to decreased NA enzymatic activity above about pH
5 indicates the presence of a pathogen other than influenza virus in the sample;

(ii) maximal NA enzymatic activity at about pH 6 to about pH 8 coupled with comparatively diminished NA enzymatic activity
above about pH 8 indicates the presence of influenza virus in the sample; and

(iii) substantially steady NA enzymatic activity from about pH 6 to about pH 10 indicates the presence of a pathogen other
than influenza virus in the sample; and

(e) treating the patient with an antiviral drug when the presence of influenza virus in the sample is indicated.

US Pat. No. 9,476,149

METHODS FOR ELECTROSPINNING HYDROPHOBIC COAXIAL FIBERS INTO SUPERHYDROPHOBIC AND OLEOPHOBIC COAXIAL FIBER MATS

University of Cincinnati,...

1. A superhydrophobic coaxial fiber mat comprising an electrospun hydrophobic coaxial fiber, wherein:
the electrospun hydrophobic coaxial fiber comprises an electrospinnable polymer coated with a hydrophobic sheath material,
the hydrophobic sheath material comprises a fluoropolymer comprising an amorphous copolymer of polytetrafluoroethylene and
2,2-bis(trifluoromethyl)-4,5-difluoro-1,3-dioxole, the superhydrophobic coaxial fiber mat comprises from 1 weight percent
to 10 weight percent of the hydrophobic sheath material; and

wherein the superhydrophobic coaxial fiber mat possesses a contact angle greater than or equal to 150° with water.

US Pat. No. 9,320,472

APPARATUSES AND METHODS FOR NEUROLOGICAL STATUS EVALUATION USING ELECTROMAGNETIC SIGNALS

University Of Cincinnati,...

1. A biological status evaluation apparatus comprising:
a signal generator configured to generate an electromagnetic signal at one or more frequencies;
a transmitting antenna electrically coupled to the signal generator, wherein the transmitting antenna is configured to transmit
the electromagnetic signal;

a receiving antenna positioned proximate to the transmitting antenna such that an evaluation space is defined between the
transmitting antenna and the receiving antenna, wherein:

the evaluation space is configured to receive a biological tissue under evaluation such that the biological tissue under evaluation
does not contact the transmitting antenna or the receiving antenna; and

the receiving antenna receives a modulated electromagnetic signal comprising the electromagnetic signal after propagation
through the biological tissue under evaluation;

a spectrum analyzer coupled to the receiving antenna, wherein the spectrum analyzer receives the modulated electromagnetic
signal and samples spectrum data of the modulated electromagnetic signal; and

a computing device coupled to the spectrum analyzer, wherein the computing device:
calculates an evaluation parameter based at least in part on sampled spectrum data of the modulated electromagnetic signal,
wherein said evaluation parameter is an energy difference between the transmitted electromagnetic signal and the received
modulated signal indicative of electromagnetic absorption in the tissue; and

provides a neurological status indicator of the biological tissue under evaluation based at least in part on the evaluation
parameter.

US Pat. No. 9,216,171

METHODS OF PREVENTING ISCHEMIC INJURY USING PERIPHERAL NOCICEPTIVE STIMULATION

University of Cincinnati,...

1. A method of inhibiting ischemia-related cardiac tissue damage in a human subject via remote sensory nerve stimulation,
the method comprising the steps of:
(a) identifying a human subject at risk for ischemia-related cardiac tissue damage; and
(b) topically administering a therapeutically effective transcutaneous electric stimulation to a predetermined region of skin
selected from (1) a region of abdominal skin containing sensory nerves from which signal travels to dorsal root ganglia at
a thoracic vertebra level at or below the T7 level and encircling the subject and (2) partial regions within said region of
abdominal skin containing sensory nerves from which signal travels to dorsal root ganglia at a thoracic vertebra level at
or below the T7 level and encircling the subject

wherein said transcutaneous electric stimulation has a voltage of 1-30 volts and is a pulsing electric stimulation adapted
to remotely stimulate a sensory nerve, thereby inhibiting ischemia-related cardiac tissue damage.

US Pat. No. 9,777,279

METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING KV1.3 ION CHANNELS WITH FUNCTIONALIZED LIPID-DERIVED NANOVESICLES

University of Cincinnati,...

1. A pharmaceutical composition comprising: lipid nanovesicles functionalized with surface-bound antibody selective for a
membrane protein unique to a target subset of immune system cells; and siRNA effective for inhibiting expression of an ion
channel of the target subset cells upon transfection, said siRNA encapsulated within the lipid nanovesicle.

US Pat. No. 9,122,005

ELECTROWETTING RETROREFLECTOR DEVICES, SYSTEMS, AND METHODS

University Of Cincinnati,...

1. A switchable retroreflector device comprising:
a fluid vessel having an area therein;
an electrically-conductive, polar fluid occupying at least a portion of the fluid vessel;a non-polar fluid that is immiscible with the polar fluid, the non-polar fluid occupying a portion of the fluid vessel that
is not occupied by the polar fluid and that differs from the polar fluid in at least one optical property;
retroreflective surface operably coupled to the fluid vessel and configured to retroreflect light that is incident onto the
retroreflective surface as a reflected light, each of the incident light and the reflected light traveling through at least
one of the polar and non-polar fluids;

a capacitor disposed on at least a portion of the fluid vessel and in at least partial contact with the polar fluid;
a voltage source electrically coupled to the capacitor, the voltage source configured to selectively apply a voltage to the
capacitor and operable to cause the polar fluid to move within the area;

wherein the polar and non-polar fluids have different relative geometrical configurations at different applied voltages and
each one of the different geometrical configurations is operable to provide a different level of retroreflection; and

wherein the retroreflective surface has a bead reflector geometry.

US Pat. No. 9,081,171

SPECTRUM-MODULATED SMART WINDOWS

University Of Cincinnati,...

1. A window for adjusting a quantity of light in a visible spectrum and a quantity of light in a near infrared spectrum, the
window comprising:
an exterior layer;
an interior layer; and
an electrofluidic layer that is positioned between the exterior layer and the interior layer and operably coupled to the exterior
layer, the electrofluidic layer configured to:

transmit a portion of the light in the visible spectrum and reflect a portion of the light in the near infrared spectrum so
that a greater quantity of light in the visible spectrum is transmitted as compared to the quantity of light in the near infrared
spectrum when operating in a first selectable state, and transmit a portion of the light in the near infrared spectrum and
reflect a portion of the light in the visible spectrum so that a greater quantity of light in the near infrared spectrum is
transmitted as compared to the quantity of light in the visible spectrum when operating in a second selectable state as compared
to the first selectable state.

US Pat. No. 9,911,985

INORGANIC MICROPOROUS ION EXCHANGE MEMBRANES FOR REDOX FLOW BATTERIES

University Of Cincinnati,...

1. A redox flow battery comprising:
a first oxidizing reaction chamber and a second reducing reaction chamber separated by a separator;
wherein said separator comprises a zeolite layer on a support, wherein said zeolite layer comprises aluminosilicate having
a silicon to aluminum ratio of at least 10;

wherein said battery operates on electrode reactions of dissolved redox metal ion couples separated by said separator.
US Pat. No. 9,795,618

METHODS AND COMPOSITIONS FOR SUPPRESSING IGE-MEDIATED ANAPHYLAXIS

University of Cincinnati,...

1. A method of suppressing IgE-mediated anaphylaxis comprising administering to a subject in need thereof a combination of
an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists, wherein the antihistamine
is triprolidine, the one or more beta-adrenergic agonists comprises albuterol, and the one or more tyrosine kinase antagonists
comprises fostamatinib.

US Pat. No. 9,357,970

APPARATUSES AND METHODS FOR NEUROLOGICAL STATUS EVALUATION USING ELECTROMAGNETIC SIGNALS

University Of Cincinnati,...

1. A biological status evaluation apparatus comprising:
a signal generator configured to generate an electromagnetic signal at one or more frequencies;
a transmitting antenna electrically coupled to the signal generator, wherein the transmitting antenna is configured to transmit
the electromagnetic signal;

a receiving antenna positioned proximate to the transmitting antenna such that an evaluation space is defined between the
transmitting antenna and the receiving antenna, wherein:

the evaluation space is configured to receive a biological tissue under evaluation such that the biological tissue under evaluation
does not contact the transmitting antenna or the receiving antenna; and

the receiving antenna receives a modulated electromagnetic signal comprising the electromagnetic signal after propagation
through the biological tissue under evaluation;

a spectrum analyzer coupled to the receiving antenna, wherein the spectrum analyzer receives the modulated electromagnetic
signal and samples spectrum data of the modulated electromagnetic signal; and

a computing device coupled to the spectrum analyzer, wherein the computing device:
calculates an evaluation parameter based at least in part on sampled spectrum data of the modulated electromagnetic signal,
wherein said evaluation parameter is an energy difference between the transmitted electromagnetic signal and the received
modulated signal indicative of electromagnetic absorption in the tissue; and

provides a neurological status indicator of the biological tissue under evaluation based at least in part on the evaluation
parameter.

US Pat. No. 9,266,941

APOLIPOPROTEIN AIV AS AN ANTIDIABETIC PEPTIDE

University of Cincinnati,...


wherein, X1 is G, A or V;

X2 is E or K;

X3 is T or S; and

X4 is Q or H,

optionally the polypeptide is glycosylated.

US Pat. No. 9,113,559

PRESSURE RECONFIGURED ELECTROMAGNETIC DEVICES

University of Cincinnati,...

1. A reconfigurable electromagnetic device comprising:
a first layer having a first surface;
a second layer having a second surface facing said first surface;
said first and second surfaces spaced from each other and defining an area between said surfaces;
said second surface having at least one trench;
said area containing first and second immiscible fluids;
said first immiscible fluid being an electro-fluid;
said area further including an evacuation path for said second fluid;
whereby withdrawing said second fluid from said area causes said first fluid to fill said trench and
whereby reintroducing said second fluid into said area causes said first fluid to withdraw from said trench.

US Pat. No. 9,669,203

METHODS OF ENHANCING DELIVERY OF DRUGS USING ULTRASONIC WAVES AND SYSTEMS FOR PERFORMING THE SAME

University of Cincinnati,...

1. A method for inducing and passively detecting stable cavitation for targeted drug delivery across a biological membrane,
comprising:
administering vesicles comprising a nucleating agent and a therapeutic drug to a target vascular system of a patient;
providing intermittent active intervals of ultrasonic exposure substantially throughout a targeted treatment zone within the
vascular system of the patient, said active intervals each lasting an active interval duration and being separated by rest
periods, each rest period lasting a rest period duration during which no ultrasonic energy is provided, wherein the ultrasonic
exposure is produced by a source transducer at a specified fundamental frequency, amplitude, duty cycle, and duration;

detecting a scattered ultrasonic wave, wherein the scattered ultrasonic wave is received by a detection transducer and the
scattered ultrasonic wave comprises a derivative frequency of the fundamental ultrasonic frequency comprising at least one
of a subharmonic frequency and an ultraharmonic frequency, wherein detection of the derivative frequency is indicative of
stable cavitation; and

modifying the active interval duration and rest period duration to maintain stable cavitation by leaving the source transducer
on when scattered ultrasonic waves of the derivative frequency are detected, and initiating a rest period when scattered ultrasonic
waves of the derivative frequency decrease or are not detected.

US Pat. No. 9,585,870

COMPOSITIONS AND METHODS FOR IMPROVING LACTATION

UNIVERSITY OF CINCINNATI,...

1. A method for the prevention and/or treatment of periparturient hypocalcemia (milk fever) in lactating female mammals, the
method comprising administering to a female mammal in need of such treatment a therapeutically effective amount of a pharmaceutical
agent that increases serotonergic signaling wherein the pharmaceutical agent is administered at the onset of lactation.

US Pat. No. 9,506,855

METHOD AND SYSTEM FOR ANALYZING A COLORIMETRIC ASSAY

University Of Cincinnati,...

1. A method of analyzing a colorimetric assay to identify a value for an assay parameter, the method comprising: obtaining
an image of a first colorimetric assay; converting intensity data from at least one of the red channel, the green channel,
or the blue channels from at least a portion of the image of the first colorimetric assay to a first data point having a first
value and a second value wherein the first value and the second value indicate the chromaticity of the test colorimetric assay;
recalling a predetermined standardized curve from a storage medium, the standardized curve including a plurality of data points,
each of the plurality of data points having a third value, a fourth value, and a fifth value, the third value and fourth values
indicating the chromaticity of the data point along the standardized curve and the fifth value indicating the value of an
assay parameter associated with the third value and the fourth value; and comparing the first data point with the standardized
curve to identify the value of the assay parameter for the first colorimetric assay, wherein the image is obtained with a
device having an imaging sensor selected from the group consisting of a charge-coupled device (“CCD”) sensor, a complementary
metal-oxide-semiconductor (“CMOS”) sensor, and a contact image sensor (“CIS”).

US Pat. No. 9,211,490

ELECTROFLUIDIC TEXTILES AND CLEANING IMPLEMENTS USING SUCH ELECTROFLUIDIC TEXTILES

University of Cincinnati,...

1. A method of manipulating a fluid with a porous web of electrofluidic fibers, the method comprising:
applying a first bias voltage to a conductive core of each of the electrofluidic fibers in the porous web effective to remove
a fluid from a surface; and

applying a second bias voltage to the conductive core of the electrofluidic fibers effective to transfer the fluid from a
first reservoir onto the surface.

US Pat. No. 9,689,671

MEASURING WALL THICKNESS LOSS FOR A STRUCTURE

University Of Cincinnati,...

1. A system for measuring wall thickness in a region of interest included in a structure, comprising:
a plurality of transducers each with a magnetic flux guide configured to:
excite a preferred guided wave mode from a plurality of non-preferred guided wave modes that propagate at a non-preferred
guided mode frequency that is substantially similar to a preferred guided wave mode frequency associated with the preferred
guided wave mode, wherein the plurality of preferred guided wave modes propagate longitudinally in a A0 mode and the plurality of non-preferred guided wave modes propagate longitudinally in a S0 mode,

minimize each spurious signal associated with the non-preferred guided wave modes by adjusting an inclination angle of a Lorentz
Force field beneath each transducer with the magnetic flux guide to increase an amplitude ratio between the preferred guided
wave mode and each spurious signal associated with the non-preferred guided wave modes, and

generate the electrical signal that encodes the three-dimensional representation of the wall thickness loss distribution of
the region of interest based on a change in the preferred guided wave mode from excitation to detection;

a pre-processing system configured to convert the three-dimensional representation encoded by the propagated electrical signals
to a two-dimensional model for analysis of the wall thickness loss distribution; and

an inversion system configured to generate a wall thickness loss distribution map from the two-dimensional model, wherein
the wall thickness loss distribution map provides the wall thickness loss distribution for the region of interest.

US Pat. No. 9,555,109

METHOD OF INHIBITING CELL PROLIFERATION INDUCED BY ALTERNATIVELY SPLICED TISSUE FACTOR BY ADMINISTERING A MONOCLONAL ANTIBODY

University of Cincinnati,...

6. A method of treating a proliferating cell disorder in a subject comprising:
administering an inhibitor of asTF to the subject at a dose sufficient to inhibit cell proliferation, wherein the inhibitor
is a monoclonal anti-asTF antibody raised against a peptide sequence having SEQ ID NO: 1 and includes a first variable sequence
having SEQ ID NO: 2 and a second variable sequence having SEQ ID NO: 3, and the antibody interrupts interaction of asTF with
?-integrin to attenuate cellular proliferation.

US Pat. No. 10,071,954

HYDROGEN PEROXIDE-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS

University of Cincinnati,...

9. A pharmaceutical composition comprising:(a) a therapeutically effective amount of a compound according to claim 1; and
(b) a pharmaceutically-acceptable carrier.

US Pat. No. 9,850,705

ENERGY EFFICIENT SHADING SYSTEMS FOR WINDOWS

University of Cincinnati,...

1. A shading assembly that provides independent control of solar visible light and solar near-infrared heat transmitted through
the shading assembly to achieve at least 4 selectable states, the shading assembly comprising a first retractably shade and
a second retractable shade;
wherein a first selectable state allows transmission of visible light through the shading assembly and rejects transmission
of solar heat through the shading assembly through reflection,

wherein a second selectable state absorbs or reflects visible solar light through the shading assembly and transmits solar
heat through the shading assembly;

wherein a third selectable state transmits both visible solar light and solar heat through the shading assembly;
wherein a fourth selectable state absorbs or reflects both visible solar light and solar heat through the shading assembly;
wherein the first selectable state is transmissive to more than 40% of visible solar light and reflects more than 35% of solar
heat;

wherein the second selectable state absorbs or reflects more than 75% of visible solar light and transmits more than 50% of
solar heat;

wherein the third selectable state transmits more than 50% of visible solar light and more than 50% of solar heat;
wherein the fourth selectable state absorbs or reflects more than 75% of visible solar light and reflects more than 35% of
solar heat;

wherein the first shade and the second shade are configured to be deployable concurrently or individually to achieve said
4 selectable states.

US Pat. No. 9,732,235

CORROSION RESISTANT HYBRID SILANIZED EPOXY ESTER RESINS, COATINGS AND SURFACE PRE-TREATMENT FORMULATIONS

University Of Cincinnati,...

1. A coating formed from:
a water-soluble epoxy ester unsaturated resin;
a water-soluble polyurea;
an amine terminated siloxane and an epoxy terminated siloxane; and
a clay.
US Pat. No. 9,925,206

COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTION

UNIVERSITY OF CINCINNATI,...

1. A composition comprising a therapeutically effective amount of acidified nitrite (A-NO2?), an iron chelator agent and an antibiotic agent,wherein the iron chelator agent is EDTA or DPTA.

US Pat. No. 9,625,705

DOSING AND SEALING OF FLUID-BASED ELCTRO-OPTICAL DEVICES AND DISPLAYS

University Of Cincinnati,...

1. A method for manufacturing an electrofluidic (electrowetting) device comprising the steps of :
providing a first plate with features for holding a first fluid, filling a first fluid into features on a first plate;
providing a second plate;
sealing a second plate onto the first plate forming stacked plates with at least one cavity between the plates, and leaving
at least one fill port for a second fluid;

cooling the stacked plates to increase the viscosity of the first fluid so that the first fluid maintains a fixed position
as a second fluid is filled into the cavity; and,

filling a second fluid into the cavity.
US Pat. No. 10,071,134

THERAPEUTIC USES OF CD137POS REGULATORY T CELLS

University of Cincinnati,...

1. A method of inhibiting progression of type 1 diabetes in a mammal comprising administering to the mammal a therapeutically effective amount of CD137pos regulatory T cells.

US Pat. No. 9,753,273

ELECTROFLUIDIC DISPLAY AND METHODS FOR MAKING

University Of Cincinnati,...

1. A method for fabricating a sealed module, said module containing a polar and non-polar fluid, comprising the steps of:
providing a bottom plate with a population of patterned devices including spacer features,
applying adhesive to the exterior of each device area on the bottom plate,
laminating a freestanding porous film to the bottom plate and bonding it with the adhesive,
dispensing a first fluid into each device area,
providing a top plate with a population of patterned devices including spacer features,
applying adhesive to the top plate,
bonding the top plate to the film and bottom plate, the populations of patterned devices on the bottom plate and on the top
plate being aligned to form a population of modules,

scribing the plates and singulating the modules,
cutting the porous film,
vacuum filling a second fluid into the modules, and
end-sealing the modules.
US Pat. No. 10,124,064

ANTIMICROBIAL COMPOSITIONS OF AMINOGLYCOSIDIC ANTIBIOTICS AND ZINC ION CHELATORS SPECIFICALLY FORMULATED FOR ENHANCED INHIBITION OF BACTERIAL COLONIZATION AND ANTIBACTERIAL EFFICACY

University of Cincinnati,...

1. A method of formulating a pharmaceutical composition comprising about 0.1% gentamicin by weight and about 5 to 15 mg/ml diethylenetriamine pentaacetic acid (DTPA) as a topical formulation, the method comprising: providing a base vessel of suitable oil-in-water emulsion base maintained at about 60° C.; preparing an aliquot solution in a first vessel by adding an amount of DTPA to an amount of sterile water and mixing until uniform; transferring a specified volume of the aliquot to a second vessel and adding gentamicin sulfate while mixing until the gentamicin sulfate is substantially fully dissolved; heating the base in the base vessel to about 90° C. while stirring; filtering and transferring the entire contents of the second vessel to the base vessel; mixing until uniform; cooling to about 55° C.; transferring to a sterilization vessel and sterilizing.
US Pat. No. 9,957,332

COMPOSITIONS AND METHODS FOR TREATING COCAINE-RELATED DISORDERS

University of Cincinnati,...

1. A monoclonal antibody that specifically binds cocaine, wherein said antibody comprises:(a) a murine lambda light chain variable region CDR1 comprising SEQ ID NO: 4;
(b) a murine lambda light chain variable region CDR2 comprising SEQ ID NO: 5;
(c) a murine lambda light chain variable region CDR3 comprising SEQ ID NO: 6;
(d) a human gamma heavy chain variable region CDR1 comprising SEQ ID NO: 7;
(e) a human gamma heavy chain variable region CDR2 comprising SEQ ID NO: 8;
(f) a human gamma heavy chain variable region CDR3 comprising SEQ ID NO: 9; and
(g) a human light chain constant region.
US Pat. No. 9,682,066

METHODS OF TREATING PRIMARY BRAIN TUMORS BY ADMINISTERING LETROZOLE

University of Cincinnati,...

1. A method of treating a primary brain tumor consisting of administering to a patient in need thereof a therapeutically effective
amount of letrozole.
US Pat. No. 9,821,063

ANTIMICROBIAL COMPOSITIONS OF AMINOGLYCOSIDIC ANTIBIOTICS AND ZINC ION CHELATORS SPECIFICALLY FORMULATED FOR ENHANCED INHIBITION OF BACTERIAL COLONIZATION AND ANTIBACTERIAL EFFICACY

University of Cincinnati,...

1. A pharmaceutical composition formulated for topical application to a subject; the composition comprising about 0.1% gentamicin
by weight, 5 to 15 mg/ml diethylenetriamine pentaacetic acid (DTPA), and an oil-in-water emulsion base.

US Pat. No. 9,526,514

PATIENT-SPECIFIC ASSEMBLIES, JIGS, AND METHODS FOR A PERSONALIZED TOTAL HIP ARTHROPLASTY SYSTEM

University of Cincinnati,...

1. A patient-specific acetabular reaming and impacting assembly comprising:
a pin locating jig comprising a body having a periphery and a least three patient-specific cannulated nubs, each nub attached
to the periphery by at least one tab and having at least one surface contoured to engage a portion of an outer rim of an acetabulum
of the patient at a self-selecting position and through which a surgical pin may be inserted and secured to the outer rim
of the acetabulum, where upon removal of the body a pin rail system is formed comprising at least three surgical pins, each
secured through a nub forming a base;

a removable reamer jig comprising at least three peripheral pin holes, each hole corresponding to a pin of the pin rail system
permitting engagement of the reamer jig to the pin rail system, and an axial bore through which an acetabular reaming device
may be inserted and attached;

at least one set of spacing elements;
a removable impactor jig comprising at least three peripheral pin holes, each hole corresponding to a pin of the pin rail
system permitting sliding engagement of the impactor jig to the pin rail system, and a cup portion sized to fit into an implant
cup, and an axial bore through which an acetabular impacting device may be inserted to guide and impact the implant into position
in the acetabulum.

US Pat. No. 10,121,464

SUBBAND ALGORITHM WITH THRESHOLD FOR ROBUST BROADBAND ACTIVE NOISE CONTROL SYSTEM

Ford Global Technologies,...

1. A vehicle system comprising:an active noise control (ANC) system including a processor programmed to implement an adaptive subband filtered reference control algorithm that applies thresholds to reference and error feedback signal paths such that, responsive to broadband non-Gaussian impulsive reference signals indicative of road noise and detected via sensors, weight coefficients defining an adaptive filter of the control algorithm converge and permit the ANC system to partially cancel the road noise via a speaker.
US Pat. No. 9,868,938

METHODS FOR ACCELERATED AND ENHANCED CARDIAC DIFFERENTIATION OF IPS CELLS BY ELECTRICAL STIMULATION

University of Cincinnati,...

1. An in vitro method for the accelerated and enhanced generation of cardiomyocytes, the method comprising: applying electrical
stimulation to an embryoid body (EB) of human induced pluripotent stem cells (iPSCs) for a time period to induce cardiomyocyte
differentiation of the induced pluripotent stem cells to form cardiomyocytes without the use of exogenous growth factors,
wherein the exogenous growth factors are selected from the group consisting of bone morphogenetic proteins, wingless/INT proteins,
fibroblastic growth factors, vascular endothelial growth factor, activin A and ascorbic acid/vitamin C, wherein generation
of cardiomyocytes from human iPSCs is accelerated and enhanced when compared to in vitro generation from human iPSCs without
applying electrical stimulation.

US Pat. No. 9,655,752

METHODS FOR MAKING MAGNESIUM BIODEGRADABLE STENTS FOR MEDICAL IMPLANT APPLICATIONS

University of Cincinnati,...

1. A method for placement of a magnesium biodegradable stent for implantation in a surgically-created arteriovenous fistulae
comprising:
providing a magnesium biodegradable stent comprising a cylinder having a longitudinal length, said stent being fabricated
from magnesium foil comprising pure magnesium or magnesium alloys that are biodegradable, wherein the cylinder is configured
to be balloon-expandable and comprises a a plurality of circumferential struts; a solid upper ring located at one end of the
cylinder, and a solid lower ring located at the other end of the cylinder, said solid rings having different expansion properties
than the rest of the stent;

optionally, removing or cutting one or more of the solid rings before the stent is implanted;
creating an arteriovenous fistulae with an end to side anastomosis between an artery and a vein;
inserting the stent into the vein;
positioning the stent so a first end of the stent is aligned with an open end of the dissected vein;
suturing the vein to the artery;
incising the artery across the anastomosis;
inserting a balloon via the incision in the artery to the stent;
expanding the balloon to expand the stent; and
suturing the incision in the artery.
US Pat. No. 10,308,942

METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING KV1.3 ION CHANNELS WITH FUNCTIONALIZED LIPID-DERIVED NANOVESICLES

University of Cincinnati,...

1. A method of treating a patient suffering from a condition of the immune system characterized by overexpressed and/or hyperexcitable T-cells, the method comprising administering to the patient a composition formulated to selectively bind to a CD45RO-positive isoform of the T-cells and transfect it with siRNA, the composition comprising: lipid nanovesicles functionalized with surface-bound antibody selective for a membrane protein unique to the CD45RO-positive isoform; and siRNA effective for inhibiting expression of a Kv1.3 ion channel of the CD45RO-positive isoform cells upon transfection, said siRNA encapsulated within the lipid nanovesicle and comprising one or more Kv1.3-specific siRNA.

US Pat. No. 9,895,363

METHODS FOR MODULATING FUNCTION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) AND TREATING CANCER WITH PCNA-TARGETING COMPOUNDS

University of Cincinnati,...

1. A method for inhibiting growth of a cell, the method comprising contacting the cell with an effective amount of a compound
structurally depicted as,

wherein:
X is

 R1 is

each R4 is independently selected from the group consisting of H, halo, cyano, hydroxyl, and methyl;

R2 is


 and tautomers thereof, with the proviso that
at least one R4 is not H, and R4 on R1 is neither ortho-halo nor methyl; and

wherein the compound is provided in a concentration of from about 0.1 to about 10 ?M, and the growth of the cell is inhibited
by up to about 100%.

US Pat. No. 9,834,580

PHARMACEUTICAL COMPOSITIONS COMPRISING SELECTIVE PEPTIDE-BASED AGONISTS OF MELANOCORTIN 1 RECEPTOR

University of Cincinnati,...

1. A pharmaceutical composition comprising:
(a) a peptide agonist that binds human melanocortin 1 receptor (MC1R) selected from the group consisting of:
Ph(CH2)3CO—His-(D-1-Nal)-Arg-Trp-NH2;

Ph(CH2)3CO—His-(D-4-Bip)-Arg-NH2;

Ph(CH2)3CO—His-(D-4-Bip)-Arg-NHMe; and

Ph(CH2)3CO—His-(D-4-tBuPhe)-Arg-NH2; and

(b) one or more pharmaceutically-acceptable excipients.
US Pat. No. 9,730,980

METHOD OF TREATING TYPE I DIABETES USING APOLIPOPROTEIN A-IV

University of Cincinnati,...

1. A method for treating type I diabetes mellitus in a subject in need thereof, the method comprising administering to the
subject an effective amount of an apolipoprotein A-IV having at least 99% identity to the apolipoprotein A-IV.

US Pat. No. 9,987,632

MICROFLUIDIC METHODS FOR PASSIVE SEPARATION OF CELLS AND PARTICLES

University of Cincinnati,...

1. A microfluidic device for separating particles, comprising:a first, upstream linear microchannel having a first aspect ratio defined as a height of said microchannel divided by a width of said microchannel and a length L1 in order to allow the particles directed therein to focus into a first equilibrium position in the first microchannel,
a second, downstream linear microchannel in fluid communication with the first microchannel, the second microchannel having a second aspect ratio and a length L2, effective so that at least a portion of the particles directed into the second microchannel exit the first equilibrium position and experience a first migration away from a center axis of second microchannel and towards walls of the second microchannel, and a second migration towards a second equilibrium position, and the second migration to the second equilibrium position ends at distance X from a beginning of the second microchannel;
a plurality of outlets disposed before distance X and configured to receive the portion of the particles during the second migration thereof before the portion of the particles focus to the second equilibrium position in the second microchannel; and
wherein the first aspect ratio is greater than one and the second aspect ratio is less than one.

US Pat. No. 9,796,121

METHODS OF GROWING CARBON NANOTUBES AND FORMING A CARBON NANOTUBE THREAD

University of Cincinnati,...

1. A method of forming an array of aligned, uniform-length carbon nanotubes (CNTs) on a planar surface of a substrate, comprising:
1) providing a substrate having a planar surface;
2) depositing a composite catalyst layer on the planar surface, the composite catalyst layer comprising iron and cobalt in
an iron to cobalt weight percent ratio of from 20/80 to 50/50;

3) oxidizing the composite catalyst layer to form an oxidized composite catalyst layer;
4) reducing the oxidized composite catalyst layer to form a reduced composite catalyst layer; and
5) growing the array of aligned CNTs on the reduced composite catalyst layer.
US Pat. No. 9,938,348

STIMULATION VIA TLR4/MD-2 TO REVERSE TYPE 1 DIABETES

University of Cincinnati,...

1. A method of treating Type I diabetes in a subject, comprising the step of administering a TLR4/MD-2 specific antibody or an antigen-binding fragment thereof.

US Pat. No. 9,751,765

METHODS TO SUPERHEAT CARBON NANOTUBES

University Of Cincinnati,...

1. A method for annealing multi-walled carbon nanotubes comprising:
applying a high-frequency electromagnetic field to the carbon nanotubes; and
causing the carbon nanotubes to self-heat to a temperature and for a time effective to reduce defects and reduce a number
of walls in some of the carbon nanotubes,

wherein causing the carbon nanotubes to self-heat includes reducing the number of walls in some of the carbon nanotubes through
sublimation.

US Pat. No. 10,201,279

SWEAT SENSING DEVICE COMMUNICATION SECURITY AND COMPLIANCE

University of Cincinnati,...

1. A method of fabricating a fluid sensor, comprising:fabricating a substrate;
fabricating an electronic circuit on the substrate;
placing electronic components onto the electronic circuit by solder reflow;
fabricating at least one sensor, wherein the at least one sensor includes at least one electrode, and wherein the at least one sensor is configured to be connected to the electronic circuit;
fabricating a membrane on the at least one electrode, wherein fabricating the membrane further comprises applying an ionophore polymer coating on the at least one electrode; and
fabricating a dressing;
wherein the step of fabricating the dressing further comprises:
laser cutting a top layer medical textile;
laser cutting a microfluidic layer;
circumferentially surrounding the at least one electrode with the microfluidic layer;
laser cutting an adhesive layer; and
pressing the top layer medical textile, the microfluidic layer, the electronic circuit, and the adhesive layer for bonding.
US Pat. No. 10,202,631

MULTI-TIERED, HIGH THROUGH-PUT SCREEN FOR COMPOUNDS EFFECTIVE AGAINST BACTERIAL BIOFILM COMPOUNDS EFFECTIVE FOR INHIBITING AND ERADICATING BACTERIAL BIOFILM

University of Cincinnati,...

1. A method for controlling bacterial biofilms on a substrate, the method comprising applying a composition comprising one or more compounds set forth in Table 1 to the substrate, wherein Table 1 compounds are selected from the group consisting of:5-chloro-2-methyl-3-oxo-1,2-thiazole-4-carbonitrile;
7-(4-carbamothioylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;
1-cyclopropyl-6,8-difluoro-7-(3-hydroxyazetidine-1-yl)-4-oxoquinoline-3-carboxylic acid;
7-(4-pyridyl)-1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid;
2-[5-[4-(4,5-dihydroimidazol-1-ylmethyl)phenyl]-2-furanyl]-1H-Benzimidazole;
5-amino-2,3,3-Benzoxadiazole-4,7-dione;
6-(2,3-dihydro-2,2-dimethyl-4-benzofuranyl)-5-methyl-2,4-Quinazolinediamine;
1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-7-(4-dithiocarboxypinerazin-1-yl)-1,8-Naphthyridinyl-3-carboxylic acid;
1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-7-(4-hydroxy-1-piperidinyl)-1,8-Naphthyridine-3-carboxylic acid;
3-phenoxy-N-[4-(trifluoromethyl)phenyl]-Benzenesulfonamide;
N-(4-nitroso-2-phenyl-1H-indol-5-yl)hydroxylamine;
2-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-benzimidazol-1-yl]-N?-[(E)-(3,5-dibromo-2-hydroxyphenyl)methylidene]acetohydrazide;
N?-[(E)-(5-Bromo-2,4-dihydroxyphenyl)methylene]naphtho[2,1-b]furan-2-carbohydrazide;
(4R,4aR,7aB,8S,13aR)-rel-3,4,4a,5,6,7,7a,8-octahydro-11,12-dihydroxy-4,8-diphenyl-[1]Benzopyrano[3,2-i]quinazoline-2(1H)-thione;
N?1,N?3-Bis[(E)-(5-bromo-2-hydroxyphenyl)methylene]-2-butylmalonohydrazide;
4-[{3-[(3,4-dichlorobenzyl)oxy]phenyl)(5-hydroxy-3-methyl-1H-pyrazol-4-yl)methyl)-3-methyl-1H-pyrazol-5-ol;
2-(1H-benzoimidazol-2-YL)-3,4,6 Trichlrophenol;
Butyl (E)-2,4-dioxo-6-phenylhex-5-enoate;
Benzimidazol-5-yl)imino]methyl}phenol; and
N?-(2,4-dihydroxybenzylidene)-2-phenylquinoline-4-carbohydrazide.
US Pat. No. 9,758,593

COMPOSITIONS AND METHODS FOR TREATING COCAINE-RELATED DISORDERS

University of Cincinnati,...

1. A method for treating a cocaine-related disorder in an individual, comprising administering to the individual a therapeutic
amount of a monoclonal antibody comprising a human gamma heavy chain and a murine lambda light chain, wherein the antibody
specifically binds cocaine and is generated by immunizing a HCo7/Ko5 mouse with an antigen comprising a conjugate of benzoylecgonine
and an immunogenic carrier protein, wherein the murine lambda light chain comprises SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID
NO: 6 and wherein the human gamma heavy chain comprises SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, wherein the antibody
binds cocaine or a derivative thereof.

US Pat. No. 10,182,795

DEVICES FOR INTEGRATED, REPEATED, PROLONGED, AND/OR RELIABLE SWEAT STIMULATION AND BIOSENSING

University Of Cincinnati,...

1. An apparatus to measure or collect sweat over an extended period of time, comprising:a plurality of sweat stimulation pads, wherein each sweat stimulation pad includes: a sweat stimulant, an electrode, and a sweat stimulant carrying medium, and wherein the pad is adapted to deliver the sweat stimulant to skin to generate sweat;
one or more sweat collectors;
one or more sensors for measuring a characteristic of an analyte in sweat, wherein the sensor is in fluidic communication with the sweat collector; and
a timing circuit adapted to selectively activate and deactivate said plurality of sweat stimulation pad for one or more limited periods of time, wherein each sweat stimulation pad is selectively operable by said timing circuit.

US Pat. No. 9,999,225

SILVER NANOPARTICLE-ENHANCED PHOTOSENSITIZERS

University Of Cincinnati,...

1. A nanostructure comprising:a silver nanoparticle core;
a mesoporous silica shell that contacts the silver nanoparticle core; and
a photosensitizer adsorbed onto said mesoporous silica shell without being covalently bonded to said mesoporous silica shell.

US Pat. No. 10,188,858

METHOD AND DEVICE FOR TREATING A TISSUE WITH A HIGH FREQUENCY ELECTROMAGNETIC FIELD

University Of Cincinnati,...

1. A method of treating a wound in a tissue, the method comprising:covering the wound with a dressing consisting of a hydrogel; and
exposing the tissue having the wound to a high frequency electric field at a frequency in a range between 1 GHz and 10 GHz
continuously for a duration of at least 20 minutes per day in a non-thermal manner to induce wound healing.

US Pat. No. 10,136,831

SWEAT SENSING WITH CHRONOLOGICAL ASSURANCE

University Of Cincinnati,...

1. A sweat sensor device capable of continuous monitoring and chronological assurance comprising:one or more sweat sensors adapted to detect a specific solute in sweat and to obtain measurements of said solute in sweat over at least a first time period and a second time period;
a sweat sampling volume between a sampling site on skin and said one or more sweat sensors, said sweat sampling volume at least in part determining a sweat sampling rate; and
electronics adapted to correlate said sweat sampling rate with said measurements from said one or more sensors to provide a chronological assurance of the effective rate at which newly originated sweat reaches said one or more sweat sensors during the first and second time periods.
US Pat. No. 10,301,355

METHOD OF USING PHARMACEUTICAL COMPOSITIONS COMPRISING SELECTIVE PEPTIDE-BASED AGONISTS OF MELANOCORTIN 1 RECEPTOR

University of Cincinnati,...

1. A method of treating a skin disorder comprising administering to an individual in need thereof a therapeutic amount of a composition comprising:(a) a peptide agonist that binds human melanocortin 1 receptor (MC1R) selected from the group consisting of:
Ph(CH2)3CO-His-(D-1-Nal)-Arg-Trp-NH2;
Ph(CH2)3CO-His-(D-4-Bip)-Arg-NH2;
Ph(CH2)3CO-His-(D-4-Bip)-Arg-NHMe;
Ph(CH2)3CO-His-(D-4-tBuPhe)-Arg-NH2; and
(b) one or more pharmaceutically-acceptable excipients, wherein the administering delivers the peptide agonist to melanocytes in the skin.

US Pat. No. 10,258,262

SWEAT SENSING DEVICE COMMUNICATION SECURITY AND COMPLIANCE

University of Cincinnati,...

1. A device comprising:a sensor apparatus for sensing and analyzing at least one fluid, wherein the sensor apparatus includes:
a first layer;
an electronic layer comprising a microcontroller, a transceiver antenna coil, and at least one sensor, wherein the at least one sensor includes at least one electrode, wherein the electronic layer is adhered to the first layer; and
a microfluidic layer adhered to the first layer, wherein the microfluidic layer is positioned on a same plane as the electronic layer and surrounds the at least one sensor of the electronic layer;
wherein the first layer is operable to allow a fluid to flow through the first layer and to the at least one sensor;
wherein the at least one electrode of the at least one sensor is operable to generate at least one measurement characterizing a biomarker present in the fluid; and
wherein the sensor apparatus uses the at least one measurement to calculate at least one output associated with the biomarker of the fluid.
US Pat. No. 10,232,019

METHOD OF TREATING HYPERGLYCEMIC DISORDERS USING APOLIPOPROTEIN AIV

University of Cincinnati,...


wherein, X1 must be present and is G, A, or V;
X2 is E or K;
X3 is T or S; and
X4 is Q or H.

US Pat. No. 10,227,897

ENHANCED DRY-COOLING SYSTEM AND METHOD FOR INCREASING POWER PLANT EFFICIENCY AND OUTPUT

University of Cincinnati,...

1. A dry-cooling system for increasing power plant efficiency and output, the system comprising:a) an air-cooled condenser; and
b) an air cooling system in fluid communication with the air-cooled condenser, said air cooling system comprising:
(i) an air cooling loop, said air cooling loop comprising:
an air cooler comprising a heat exchanger, wherein the air cooler is in valve-controlled fluid communication with a source of ambient air;
a thermal energy storage unit configured to contain a thermal energy storage material; and
a system of valve-controlled conduits configured to cycle a heat transfer fluid between the heat exchanger and the thermal energy storage unit;
(ii) a recharging loop, said recharging loop comprising:
a second air cooler comprising a second heat exchanger, wherein the second air cooler is in valve-controlled fluid communication with a source of ambient air;
the thermal energy storage unit; and
a second system of valve-controlled conduits configured to cycle a second heat transfer fluid between the thermal energy storage unit and the second heat exchanger.

US Pat. No. 10,265,205

METHODS FOR MAKING MAGNESIUM BIODEGRADABLE STENTS FOR MEDICAL IMPLANT APPLICATIONS

UNIVERSITY OF CINCINNATI,...

1. A method for making a magnesium biodegradable stent for medical implant applications comprising:providing a magnesium foil comprising pure magnesium or magnesium alloys that are biodegradable;
performing a lithographic technique to configure and transfer features of the stent to both sides of the magnesium foil, wherein the lithographic technique is selected from at least one of optical photolithography, electron beam lithography, x-ray lithography, and nanoimprint lithography, or a combination of these techniques;
etching the magnesium foil by wet chemical etching or gas phase chemical etching;
rolling the magnesium foil to form a cylinder comprising a longitudinal length, two longitudinal edges, a side, and a circular cross-section having a diameter, at least two features of the cylinder comprising an upper ring and a lower ring, the rings located at each end of the longitudinal length of the cylinder;
laser welding at least a portion of the side of the magnesium cylinder; and
removing the upper and lower rings of the cylinder by etching, mechanical cutting, or laser cutting after laser welding.

US Pat. No. 10,501,857

ADDITIVE MANUFACTURING BY LOCALIZED ELECTROCHEMICAL DEPOSITION

University of Cincinnati,...

1. A method of forming a 3-D structure, comprising:depositing a voxel or layer of metal in an electrolyte bath on a substrate by:
depositing a powder to form a layer of particulate material that covers said substrate,
moving said substrate relative to an electrode according to an electrode path based on a model of the 3-D structure, and
applying a localized electric field between said electrode and said substrate as said substrate is moved to selectively electrolytically deposit a metal binder present in said electrolyte bath on said layer of particulate material, said metal binder selectively binding said particulate material only where said metal binder is deposited to form said voxel or layer of metal; and
separating said electrode from said voxel or layer of metal and repeating said steps of depositing said powder to form another layer of particulate material that covers one or more previously formed voxels or layer of metal, moving said substrate, and applying said localized electric field multiple times to deposit multiple metal voxels or layers of metal binding said particulate material, thereby forming the 3-D structure without the use of a mask.

US Pat. No. 10,395,372

SYSTEMS, MEDIA, AND METHODS FOR PRE-PROCESSING AND POST-PROCESSING IN ADDITIVE MANUFACTURING

University of Cincinnati,...

1. A system for image processing of a computer-modeled object to be fabricated, comprising:memory; and
a processor coupled to the memory, the processor being configured to:
receive object geometry data and support geometry data;
create sectional snapshots and generate a bounding box;
perform a boundary tracing operation on the sectional snapshots;
execute a contour mapping algorithm;
perform color-based segmentation of sectional snapshots and pixel segregation;
perform pixel dimension calculations utilizing a section bounding box;
perform pixel counting to calculate a sintering area and an associated time value; and
output slice contour points with respect to the object to be fabricated and the calculated sintering area and the associated time value.

US Pat. No. 10,386,628

DOSING AND SEALING OF FLUID-BASED ELECTRO-OPTICAL DEVICES AND DISPLAYS

University Of Cincinnati,...

1. A method for manufacturing an electrofluidic device, comprising:providing a first plate with features for a first fluid;
providing a second plate;
sealing the second plate onto the first plate thereby forming a stacked plate assembly with at least one cavity between the plates, and leaving at least one fill port for fluid filling;
filling a mixture of ink and oil fluids between the plates; and,
collapsing the mixture into the constituent fluids by applying light to the mixture.

US Pat. No. 10,368,847

DEVICES FOR INTEGRATED, REPEATED, PROLONGED, AND/OR RELIABLE SWEAT STIMULATION AND BIOSENSING

University of Cincinnati,...

1. A sweat stimulating and transport device capable of both transporting sweat away from a device wearer's skin and transporting sweat stimulants to the skin comprising:one or more sweat stimulating components;
one or more sensors configured to measure a characteristic of an analyte in a sweat sample;
one or more additional components, wherein the one or more additional component is one of a sweat sample transporter, a sweat stimulant transporter, and a shared microfluidic component configured to transport both the sweat sample and a sweat stimulant; and
a selective membrane separating the one or more sweat stimulating components from the one or more sensors and the one or more additional components.
US Pat. No. 10,533,163

RECOMBINANT NUCLEOSIDE-SPECIFIC RIBONUCLEASE AND METHOD OF PRODUCING AND USING SAME

University of Cincinnati,...

1. A polynucleotide encoding a cytidine-specific recombinant RNase Cusativin, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO. 4.

US Pat. No. 10,506,968

DEVICES CAPABLE OF FLUID SAMPLE CONCENTRATION FOR EXTENDED SENSING OF ANALYTES

Eccrine Systems, Inc., C...

1. A sensing device configured to receive a fluid sample, the sensing device comprising:one or more first analyte sensors for measuring a characteristic of a first analyte in the fluid sample;
a sample concentrator configured to generate a concentrated form of the fluid sample to increase a first molarity of the first analyte within the fluid sample to a second molarity, wherein the second molarity is at least two times higher than the first molarity, the sample concentrator comprising a membrane that is permeable to liquid and impervious to the first analyte, the membrane having a first surface adjacent to the fluid sample and a second surface opposite the fluid sample;
a collector for collecting the fluid sample from a body of a sensing device wearer;
a channel for transporting the fluid sample from the collector to the sample concentrator, to the one or more sensors, and away from the one or more sensors.

US Pat. No. 10,488,424

DEVICES AND METHODS FOR ANALYZING A BLOOD COAGULATION PROPERTY

University of Cincinnati,...

1. A device for analyzing a blood coagulation property in a blood sample comprising a housing having an analytical membrane partially enclosed in a housing, said analytical membrane including a porous hydrophilic sample portion, a porous hydrophilic analytical portion and a porous hydrophilic wicking portion, wherein said analytical portion has a porosity that differs from said sample portion and said analytical membrane does not include any additional reagents or pretreatments.

US Pat. No. 10,485,460

DEVICES FOR INTEGRATED INDIRECT SWEAT STIMULATION AND SENSING

University Of Cincinnati,...

1. A wearable sweat sensing device comprising:at least one sweat generation unit configured to be placed on a direct stimulation region of a surface of a wearer's skin to induce sweating underneath the at least one sweat generation unit, and also to initiate sweating in an indirect stimulation region of skin separated from the direct stimulation region along the skin surface;
at least one sweat collection unit separated from the at least one sweat generation unit by an isolation material, the at least one sweat collection unit capable of collecting one or more sweat samples from the wearer's skin, the at least one sweat collection unit being located above the indirect stimulation region when the sweat sensing device is located on the wearer's skin to collect sweat sample; and
at least one sensing mechanism in fluid communication with the at least one sweat collection unit for detecting one or more components in the sweat sample.

US Pat. No. 10,471,249

ENHANCED ANALYTE ACCESS THROUGH EPITHELIAL TISSUE

University of Cincinnati,...

1. A device comprising:an agent for enhancing a paracellular permeability of a device wearer's epithelial tissue;
an iontophoresis electrode and a counter electrode, which are configured to increase the concentration of at least one analyte in a biofluid by the following: using iontophoresis to transport the agent into the epithelial tissue, and using reverse iontophoresis to at least partially cause an advective flow of the biofluid from the epithelial tissue into the device; and
a collector for transporting the biofluid from the epithelial tissue into the device.
US Pat. No. 10,464,974

NEUROSPORA CRASSA STRAINS WITH AMPLIFIED EXPRESSION OF CELLULASES AND PRODUCTION OF BIOFUEL THEREFROM

University of Cincinnati,...

1. A transgenic strain of Neurospora crassa engineered to comprise a synthetic positive feedback loop for a transcriptional activator of cellulase expression encoded by N. crassa clr-1 gene or N. crassa clr-2 gene, wherein the strain has been genetically modified by operably linking a promoter of a gene encoding cellobiohydrolase-1 (Pcbh-1) to the N. crassa clr-1 or N. crassa clr-2 genes.

US Pat. No. 10,506,936

APPARATUSES AND METHODS FOR NEUROLOGIC STATUS EVALUATION USING ELECTROMAGNETIC SIGNALS

University Of Cincinnati,...

1. A biological status evaluation system, comprising:a signal generator configured to generate an electromagnetic signal at one or more frequencies;
a transmitting antenna including a transmitting antenna impedance and configured to transmit the electromagnetic signal;
a receiving antenna including a receiving antenna impedance and positioned relative to the transmitting antenna such that an evaluation space is defined between the transmitting antenna and the receiving antenna, wherein the evaluation space is configured to receive a biological tissue; and
a computing device configured to:
analyze a modulated electromagnetic signal after the transmitted electromagnetic signal propagates through the biological tissue,
calculate an evaluation parameter based on an energy difference between the transmitted electromagnetic signal and the modulated electromagnetic signal, wherein the evaluation parameter is indicative of electromagnetic absorption in the biological tissue, and is calculated by:

where:
? is the evaluation parameter,
VT is the voltage at the transmitting antenna,
VR is the voltage at the receiving antenna,
ZT(?) is the magnitude of the transmitting antenna impedance,
ZR(?) is the magnitude of the receiving antenna impedance,
?0 is a lower bound of a sampled frequency spectrum, and
?1 is an upper bound of the sampled frequency spectrum, and
generate a biological status indicator of the biological tissue based on the evaluation parameter.

US Pat. No. 10,500,227

BIOACTIVE GAS-ENCAPSULATED ECHOGENIC LIPOSOMES AND METHODS FOR TREATING CARDIOVASCULAR DISEASE

University of Cincinnati,...

1. A microbubble comprising an at least partially pegylated phospholipid shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy, wherein X is 3 and Y is 8, wherein the ratio of NO to CxFy is about 1:1 or about 1:9 by volume.

US Pat. No. 10,420,346

SILVER NANOPARTICLE-ENHANCED PHOTOSENSITIZERS

University Of Cincinnati,...

1. A method of killing fungi comprising:contacting fungi with a nanostructure comprising a silver nanoparticle core, a mesoporous silica shell, and a photosensitizer to form a blend; and
exposing said blend to light.

US Pat. No. 10,408,836

METHODS OF DETECTING INFLUENZA VIRUS

University of Cincinnati,...

1. A method of diagnosing and treating influenza in a human patient, the method comprising:(a) providing a biological sample obtained from the patient, wherein the sample is suspected of comprising influenza virus;
(b) subjecting the sample to size fractionation whereby pathogens larger than influenza virus are removed from the sample;
(c) contacting the sample with a substrate for indicating NA enzymatic activity, wherein said contacting is carried out under reaction conditions of from about pH 6 to about pH 8;
(d) measuring NA enzymatic activity in the sample, wherein detection of NA enzymatic activity indicates presence of influenza virus in the sample;
(e) diagnosing the patient with influenza when the presence of influenza virus in the sample is indicated; and
(f) administering an antiviral drug selected from the group consisting of oseltamivir, zanamivir, peramivir, and R-125489 to the diagnosed patient.

US Pat. No. 10,553,793

SYSTEMS AND METHODS FOR GATED-INSULATOR RECONFIGURABLE NON-VOLATILE MEMORY DEVICES

University of Cincinnati,...

1. A method of switching a resistive state in a non-volatile multi-terminal resistive random access memory (RRAM) device, the method comprising:applying a voltage bias with an at least first gate of the non-volatile multi-terminal RRAM device, the non-volatile multi-terminal RRAM device further including a first electrode, a second electrode, and a metal oxide defining a conduction path positioned between the first electrode and the second electrode; and
based on a polarity of the voltage bias applied, switching the resistive state in the conductance path between a low resistance state (LRS) and a high resistance state (HRS) in the conduction path.

US Pat. No. 10,473,914

ELECTROFLUIDIC DISPLAY AND METHODS FOR MAKING

University of Cincinnati,...

1. A method for manufacturing a freestanding film, comprising:providing a carrier substrate,
depositing a photo-curable material on the carrier substrate,
forming a diffuser pattern in the photo-curable material, the diffuser pattern defining a total population of through holes that includes a first population of through holes having an average diameter between 4 micrometers and 40 micrometers and a standard deviation of less than 25%;
selectively curing the photo-curable material, leaving uncured material in the diffuser pattern of through holes,
dissolving away the uncured material,
depositing a metal layer on the cured material, the metal layer defining a template for the diffuser pattern of through holes;
removing the cured material from the carrier substrate, and
using the template to fabricate the freestanding film.

US Pat. No. 10,400,242

METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND NANOPARTICLE COMPLEXES OF MIR-22 UTILIZED THEREIN

University of Cincinnati,...

1. A nanoparticle delivery system designed for sustained delivery of microRNA-22(miR-22) to acute myeloid leukemia (AML) cells, the nanoparticle delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-22, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor.
US Pat. No. 10,501,556

COMPOSITIONS AND METHODS FOR TREATING COCAINE-RELATED DISORDERS

University of Cincinnati,...

1. A monoclonal antibody comprising a human gamma heavy chain and a human kappa light chain, wherein the human gamma heavy chain comprises SEQ ID NO: 2 and the human kappa light chain and comprises SEQ ID NO: 3 or SEQ ID NO: 14.
US Pat. No. 10,456,483

GAS-ENCAPSULATED ACOUSTICALLY RESPONSIVE STABILIZED MICROBUBBLES AND METHODS FOR TREATING CARDIOVASCULAR DISEASE

University of Cincinnati,...

1. An acoustically responsive microbubble comprising:a phospholipid monolayer shell comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG 2000),
an encapsulated bioactive gas selected from the group consisting of nitric oxide, xenon gas, and hydrogen sulfide, and
an encapsulated perfluorocarbon gas of the formula CxFy,
wherein X=3 and Y=8, and wherein a volume ratio of bioactive gas to CxFy is from about 10:1 to about 1:10.

US Pat. No. 10,405,538

PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME

UNIVERSITY OF CINCINNATI,...

1. A method for preserving platelet function and/or activity in a platelet subjected to cold storage comprising contacting said platelet with a composition comprising a RHOA inhibitor selected from:or pharmaceutically acceptable salt thereof,or pharmaceutically acceptable salt thereof, or combinations thereof.
US Pat. No. 10,598,662

DIAGNOSTIC ASSAYS AND METHODS OF TREATING PNEUMONIA, SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

University of Cincinnati,...

1. An in vitro method for diagnosing and treating sepsis in a human patient, the method comprising:(a) contacting at least a portion of a biological sample from the patient consisting essentially of microparticles isolated via differential centrifugation with reagents for detection and/or quantification of neutrophil-derived microparticles, wherein the biological sample is selected from the group consisting of abdominal irrigation fluid and peritoneal waste fluid;
(b) determining a level of neutrophil-derived microparticles based on the contacting in step (a);
(c) diagnosing sepsis in the patient when the determined level of neutrophil-derived microparticles is elevated relative to a cutoff value of the neutrophil-derived microparticles; and
(d) treating the diagnosed patient for sepsis.
US Pat. No. 10,568,945

COMPOSITIONS AND METHODS FOR INDUCING LIVER REGENERATION BY ADMINISTERING HEPATOCYTE-DERIVED EXOSOMES

University of Cincinnati,...

1. A method of inducing liver regeneration in a patient suffering from a liver injury associated with liver ischemia/reperfusion, the method comprising administering to the patient a therapeutic amount of exosomes formulated as an injectable suspension comprising a stable oil-in-water emulsion of lipid layer-encapsulated droplets, whereby liver regeneration is induced, and wherein a therapeutic amount is defined as an amount at least sufficient to result in a detectable increase in liver mass, wherein the exosomes are derived from a primary hepatocyte of a subject.

US Pat. No. 10,512,913

MICROFLUIDIC METHODS FOR PASSIVE SEPARATION OF CELLS AND PARTICLES

University of Cincinnati,...

1. A microfluidic device for separating a plurality of particles from a fluid medium, comprising:a microchannel having a first aspect ratio and a length L1 in order to allow the particles directed therein to focus into a first equilibrium position in the microchannel, and
a chamber in fluid communication with the microchannel and having a second aspect ratio, the chamber further comprising:
a first capture portion having a first chamber outlet, the first chamber outlet being separated from the microchannel by a first wall,
a second capture portion symmetric with the first capture portion, the second capture portion having a second chamber outlet, the second chamber outlet being separated from the microchannel by a second wall,
a main outlet in a third wall opposite the first and second walls, and
a main flow area in the chamber between the microchannel and main outlet, the main flow area also defined as being between the first and second capture portions;
wherein:
upon entering the chamber, the equilibrium position of the particles changes and the particles experience a first migration away from a center axis of the chamber,
when the first migration causes the particles to leave the main flow area, the particles migrate into the capture portions,
when the particles remain in the main flow area during the first migration, the particles further experience a second migration towards a second equilibrium position and are directed into the main outlet; and
the first and second chamber outlets communicating with the first and second capture portions, the first and second chamber outlets receiving particles that migrate into the first and second capture portions.
US Pat. No. 10,513,688

METHODS FOR ACCELERATED AND ENHANCED CARDIAC DIFFERENTIATION OF IPS CELLS BY ELECTRICAL STIMULATION

University of Cincinnati,...

1. A method of treating a cardiac disorder in a patient in need thereof, the method comprising:applying electrical stimulation in vitro to embryoid bodies of human induced pluripotent stem cells for a time period to induce cardiomyocyte differentiation of the embryoid bodies to form autologous cardiomyocytes without the use of exogenous growth factors consisting of bone morphogenetic proteins, wingless/INT proteins, fibroblastic growth factors, vascular endothelial growth factor, activin A, and ascorbic acid/vitamin C; and
delivering via intramyocardial implantation an effective amount of one or more of the formed autologous cardiomyocytes into a heart of the patient,
wherein the cardiac disorder is tissue damage after myocardial infarction.
US Pat. No. 10,457,738

STIMULATION VIA TLR4/MD-2 TO REVERSE TYPE 1 DIABETES

University of Cincinnati,...

1. A method of treating Type I diabetes in a subject, comprising administering an agonistic monoclonal antibody to Toll-Like Receptor 4 (TLR4).

US Pat. No. 10,639,015

DEVICES WITH REDUCED SWEAT VOLUMES BETWEEN SENSORS AND SWEAT GLANDS

University of Cincinnati,...

1. A sweat sensor device for sensing sweat on the skin comprising:one or more sweat sensors; and
a volume-reducing component that provides a dominantly vertical pathway for sweat between and sweat glands and the one or more sweat sensors when said device is positioned on said skin,
wherein said volume-reducing component is selected from the group consisting of a volume-reducing material and a pressure-permeated component, a sweat dissolvable material, a mechanically compliant material for conforming to a surface of said skin, an adhesive with a vertically anisotropic sweat pathway, the adhesive preventing horizontal movement of sweat, microcapsules including a barrier material, and combinations thereof.
US Pat. No. 10,633,663

THERAPEUTIC STRATEGIES FOR OVARIAN CANCER: AMHR2-RNA APTAMER

University of Cincinnati,...

1. An aptamer, comprising a nucleotide sequence having at least 95% sequence homology with at least 24 consecutive nucleotides of the nucleotide sequence set forth in SEQ ID NO:4.
US Pat. No. 10,583,103

METHOD OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH PROBENECID

University of Cincinnati,...

1. A method of treating heart failure with preserved ejection fraction (HFpEF) in a subject comprising intravenously infusing an amount of probenecid to achieve a plasma concentration effective to treat the cardiac dysfunction heart failure with preserved ejection fraction in the subject.

US Pat. No. 10,665,349

METHODS FOR DETERMINING RISK AND TREATING DISEASES AND CONDITIONS THAT CORRELATE TO WEATHER DATA

University of Cincinnati,...

1. A method of reducing a risk of a subject residing in climate region Cfa and predisposed to experiencing weather-associated adverse events for experiencing a new onset migraine headache (NOH) on a given day, the method comprising:a) determining a relevant season in which the given day falls;
b) determining whether the given day is an upper, middle or lower barometric pressure (BP) tertile day;
c) selecting an equation specific to the determined relevant season and the determined BP tertile from the group consisting of:
[season=W,BP tertile=low]R=e[?0+?1A+?2B]+N+? or 1=e[?0+?1A+?2A(exp)2+?3B+?4B(exp)2]+N+?  1)
[season=W,BP tertile=mid]R=e[?0+?1A+?2B]+N+?  2)
[season=W,BP tertile=high]R=e[?0+?1A+?2C]+N+?  3)
[season=S,BP tertile=low]R=e[?0+?1E]+N+?  4)
[season=S,BP tertile=mid]R=e[?0+?1G+?2F]+N+?  5)
[season=S,BP tertile=high]R=e[?0+?1H]+N+?  6)
wherein
R=risk of a given day being a upper tertile incident rate new onset headache day (UT-IR-NOH);
N=number of subjects in a cohort eligible to have a NOH on a given day and is a denominator in an IR-NOH calculation;
A=BP 24 hour differential mean;
B=wind speed (WS) 24 hour differential maximum;
C=dry bulb temperature (DBT) 24 hour differential mean;
E=BP 24 hour differential maximum;
F=DBT daily mean;
G=BP daily mean;
H=relative humidity (RH) 24 hour differential mean; and
?=an error term of GEE regression modeling;
d) entering weather variable data for the given day into the selected equation to yield an assessment of the risk; and
e) administering a migraine headache prophylactic treatment to the subject when the risk of experiencing a new onset migraine headache is assessed as greater than 50%.

US Pat. No. 10,656,493

TWO PARTICLE ELECTROPHORETIC LAMINATE FOR USE WITH SMART WINDOWS

University of Cincinnati,...

1. A laminate including electro kinetic pixels comprising:a transparent first layer coated with a planar first electrode;
a second layer coated with a planar second electrode;
a foraminous insulating third layer between said first layer and said second layer, said foraminous insulating third layer comprising a plurality of holes that extend to the second electrode;
a third electrode having a grid structure;
an insulating fourth layer contacting said first electrode and said third electrode, and insulating said first electrode from said third electrode;
a cell gap between said insulating fourth layer and said second electrode;
said cell gap including a colloidal dispersion of first particles and second particles;
said first particles having a first charge and a first optical property;
said second particles having a second charge different from said first charge and a second optical property different from said first particle; and
wherein said third electrode is separated from said first and second electrodes.